Literature DB >> 33122338

Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis.

Ayodeji Adegunsoye1,2,3, Julie Morisset4,3, Chad A Newton5, Justin M Oldham6, Eric Vittinghoff7, Angela L Linderholm6, Mary E Strek8, Imre Noth9, Christine Kim Garcia10, Paul J Wolters7, Brett Ley7.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 33122338      PMCID: PMC8104021          DOI: 10.1183/13993003.02872-2020

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  14 in total

1.  Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis.

Authors:  Chad A Newton; David Zhang; Justin M Oldham; Julia Kozlitina; Shwu-Fan Ma; Fernando J Martinez; Ganesh Raghu; Imre Noth; Christine Kim Garcia
Journal:  Am J Respir Crit Care Med       Date:  2019-08-01       Impact factor: 21.405

2.  Short lung transplant donor telomere length is associated with decreased CLAD-free survival.

Authors:  Hilary E Faust; Jeffrey A Golden; Raja Rajalingam; Angelia S Wang; Gary Green; Steven R Hays; Jasleen Kukreja; Jonathan P Singer; Paul J Wolters; John R Greenland
Journal:  Thorax       Date:  2017-04-26       Impact factor: 9.139

3.  Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

Authors:  Oliver Distler; Kristin B Highland; Martina Gahlemann; Arata Azuma; Aryeh Fischer; Maureen D Mayes; Ganesh Raghu; Wiebke Sauter; Mannaig Girard; Margarida Alves; Emmanuelle Clerisme-Beaty; Susanne Stowasser; Kay Tetzlaff; Masataka Kuwana; Toby M Maher
Journal:  N Engl J Med       Date:  2019-05-20       Impact factor: 91.245

4.  Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. Reply.

Authors:  Kevin R Flaherty; Athol U Wells; Kevin K Brown
Journal:  N Engl J Med       Date:  2020-02-20       Impact factor: 91.245

5.  Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis.

Authors:  Julie Morisset; Kerri A Johannson; Eric Vittinghoff; Carlos Aravena; Brett M Elicker; Kirk D Jones; Charlene D Fell; Helene Manganas; Bruno-Pierre Dubé; Paul J Wolters; Harold R Collard; Christopher J Ryerson; Brett Ley
Journal:  Chest       Date:  2016-11-03       Impact factor: 9.410

6.  Rare Protein-Altering Telomere-related Gene Variants in Patients with Chronic Hypersensitivity Pneumonitis.

Authors:  Brett Ley; Dara G Torgerson; Justin M Oldham; Ayodeji Adegunsoye; Shuo Liu; Jie Li; Brett M Elicker; Travis S Henry; Jeffrey A Golden; Kirk D Jones; Amy Dressen; Brian L Yaspan; Joseph R Arron; Imre Noth; Thomas J Hoffmann; Paul J Wolters
Journal:  Am J Respir Crit Care Med       Date:  2019-11-01       Impact factor: 21.405

7.  Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation.

Authors:  Bridget D Stuart; Joyce S Lee; Julia Kozlitina; Imre Noth; Megan S Devine; Craig S Glazer; Fernando Torres; Vaidehi Kaza; Carlos E Girod; Kirk D Jones; Brett M Elicker; Shwu-Fan Ma; Rekha Vij; Harold R Collard; Paul J Wolters; Christine Kim Garcia
Journal:  Lancet Respir Med       Date:  2014-06-16       Impact factor: 30.700

8.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

9.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Roland M du Bois; Ganesh Raghu; Arata Azuma; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Kevin R Flaherty; David M Hansell; Yoshikazu Inoue; Dong Soon Kim; Martin Kolb; Andrew G Nicholson; Paul W Noble; Moisés Selman; Hiroyuki Taniguchi; Michèle Brun; Florence Le Maulf; Mannaïg Girard; Susanne Stowasser; Rozsa Schlenker-Herceg; Bernd Disse; Harold R Collard
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

10.  Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis.

Authors:  Ayodeji Adegunsoye; Justin M Oldham; Evans R Fernández Pérez; Mark Hamblin; Nina Patel; Mitchell Tener; Deepa Bhanot; Lacey Robinson; Sam Bullick; Lena Chen; Scully Hsu; Matthew Churpek; Donald Hedeker; Steven Montner; Jonathan H Chung; Aliya N Husain; Imre Noth; Mary E Strek; Rekha Vij
Journal:  ERJ Open Res       Date:  2017-08-17
View more
  7 in total

1.  Editorial: Fibrotic Lung Disease-"Lumping" the Progressive Phenotype.

Authors:  Tejaswini Kulkarni; Sydney B Montesi; Bridget F Collins
Journal:  Front Med (Lausanne)       Date:  2022-05-31

2.  Relevance of RNA N6-Methyladenosine Regulators for Pulmonary Fibrosis: Implications for Chronic Hypersensitivity Pneumonitis and Idiopathic Pulmonary Fibrosis.

Authors:  Yiyi Zhou; Chen Fang; Qinying Sun; Yuchao Dong
Journal:  Front Genet       Date:  2022-07-14       Impact factor: 4.772

3.  Short-term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitis.

Authors:  Claudio Macaluso; Cristina Boccabella; Maria Kokosi; Nishanth Sivarasan; Vasilis Kouranos; Peter M George; George Margaritopoulos; Philip L Molyneaux; Felix Chua; Toby M Maher; Gisli R Jenkins; Andrew G Nicholson; Sujal R Desai; Anand Devaraj; Athol U Wells; Elisabetta A Renzoni; Carmel J W Stock
Journal:  Respirology       Date:  2022-01-12       Impact factor: 6.175

Review 4.  Familial Pulmonary Fibrosis: Genetic Features and Clinical Implications.

Authors:  David Zhang; Chad A Newton
Journal:  Chest       Date:  2021-06-26       Impact factor: 9.410

Review 5.  Challenges in the Diagnosis and Management of Fibrotic Hypersensitivity Pneumonitis: A Practical Review of Current Approaches.

Authors:  Teng Moua; Tananchai Petnak; Antonios Charokopos; Misbah Baqir; Jay H Ryu
Journal:  J Clin Med       Date:  2022-03-08       Impact factor: 4.241

Review 6.  Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response.

Authors:  Willis S Bowman; Gabrielle A Echt; Justin M Oldham
Journal:  Front Med (Lausanne)       Date:  2021-05-10

Review 7.  Telomeres in Interstitial Lung Disease.

Authors:  Carmel J W Stock; Elisabetta A Renzoni
Journal:  J Clin Med       Date:  2021-03-30       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.